Clinical Trials Logo
  1. Home
  2. Anti-Infective Agents
  3. NCT01690533

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

Anti-Infective Agents Clinical Trial

Official title:
Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

Clinical Trial Summary

The objective of this study is to assess the efficacy and safety of Avelox Tablet 400 mg (hereinafter as "Avelox") in treating secondary infection of chronic respiratory disease.It is a local prospective and observational study of patients who have received Avelox tablets for Laryngopharyngitis, Tonsillitis, Bronchitis acute, Pneumonia, Secondary infection in chronic respiratory diseases, Sinusitis. A total of 500 patients are to be enrolled and assessed during the period of treatment with Avelox.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01690533
Study type Observational
Source Bayer
Contact
Status Completed
Phase
Start date May 13, 2008
Completion date July 19, 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT03279120 - Safety, PK, and PD Study of IVRs Releasing TFV and LNG Phase 1
Not yet recruiting NCT03793946 - A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant N/A
Completed NCT01073540 - Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension Phase 1
Completed NCT01073553 - Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules Phase 1
Terminated NCT04489420 - Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM Phase 1
Completed NCT01231763 - Acceptability Study of Vaginal Films for HIV Prevention N/A
Completed NCT01244698 - Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Phase 4
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT01105208 - Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension Phase 1
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Completed NCT02046512 - Probiotics to Promote Intestinal Health Phase 4
Completed NCT04210713 - Neuroimmune Dysfunction in Alcohol Use Disorder Phase 1
Completed NCT04448665 - Compliance of Initial Empiric Antimicrobial Therapy
Completed NCT05979207 - Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum Phase 1
Recruiting NCT02242968 - Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products